Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MYB rearrangements in Adenoid Cystic Carcinoma: protagonists or secondary characters?

Project description

The role of MYB rearrangements in cancer

Adenoid cystic carcinoma (ACC) is a rare cancer with varying clinical behaviour depending on primary tumour site. ACCs harbour rearrangements of the MYB gene family of transcription factors resulting from chromosomal translocations. The scope of the EU-funded SALMYB project is to identify the cells that carry MYB rearrangements, elucidate their function and develop MYB-targeted therapies. Using state-of-the-art methods in molecular and cellular biology as well as genetic and tissue engineering, scientists will decipher the impact of MYB rearrangements on cell morphology, differentiation, proliferation, migration and invasion. The project's results will extend to other malignancies bearing MYB aberrations.

Objective

Adenoid cystic carcinoma (ACC) is both a rare disease (limited scientific data and professional expertise) and a cancer (complex tumour biology and evasion of conventional therapies). Clinical behaviour differs depending on primary tumour site; salivary gland ACC has poorer prognosis than breast ACC. A majority of ACC harbour MYB rearrangements resulting from chromosomal translocations, with the fusion of MYB and NFIB or MYBL1 and NFIB being the most frequent. The role of translocations in tumourigenesis and whether cells from different primary sites respond differently has not been determined. Identification of specific cell types carrying the translocation and location within the tumour microenvironment might enable development of MYB target-therapies. Our main objective is to elucidate the function of MYB rearrangements in normal salivary and mammary gland cells and the expression of the novel fusion genes in salivary gland and breast ACC. Normal human cells will be transfected with MYB-NFIB and MYBL1-NFIB fusion transcripts and fusion negative, fusion positive and combinations of cells will be compared in terms of cell morphology, differentiation, proliferation, migration and invasion. 3D models, more closely mimicking an in vivo tumour, will be compared to monolayer cultures. In situ localisation of MYB-NFIB and MYBL1-NFIB in salivary gland and breast ACC will be assessed using a novel technology, BaseScope. This ambitious research project will determine the consequences of MYB rearrangements using state-of-the-art methods in molecular and cellular biology, genetic and tissue engineering and pathological anatomy. The project has clear translational potential with social, cultural and economic impacts. Transfer of results to other cancers harbouring MYB rearrangements (eg leukaemia, colon cancer) and our methods in assessing other tumours characterised by chromosomal translocations, eg prostate, colorectal and non-small-cell lung cancer, are further outcomes.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2019

See all projects funded under this call

Coordinator

THE UNIVERSITY OF SHEFFIELD
Net EU contribution
€ 212 933,76
Address
FIRTH COURT WESTERN BANK
S10 2TN SHEFFIELD
United Kingdom
Region
Yorkshire and the Humber South Yorkshire Sheffield
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 212 933,76